This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horak, P. Articles by Krainer, M. Search for Related Content PubMed PubMed Citation Articles by Horak, P. Articles by Krainer, M.

---

Cancer Genes and Genomics

Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

¹ Clinical Division of Oncology, Department of Medicine I; ² Department of Gynecology and Obstetrics; and ³ Department of Clinical Pathology, University Hospital Vienna, Vienna, Austria

Requests for reprints: Michael Krainer, Clinical Division of Oncology, Department of Medicine I, University Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-4449; Fax: 43-1-40400-4451. E-mail: michael.krainer{at}meduniwien.ac.at

Dysregulation of apoptosis may support tumorigenesis by allowing cells to live beyond their normally intended life span. The various receptors for tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) are located on chromosome 8p21.2, a region frequently deleted in ovarian cancer. Lack of expression of TRAIL receptor 1 (death receptor 4, DR4) correlates with resistance to TRAIL-induced apoptosis in ovarian cancer cells. Reconstitution of DR4 in the TRAIL-resistant A2780 ovarian cancer cell line was investigated with the demethylating agent 5-aza-2'-deoxycytidine and transient gene transfer. Regulation of other genes in the TRAIL pathway by 5-aza-2'-deoxycytidine was assessed in DNA GeneChip experiments. Primary ovarian cancers were analyzed by methylation-specific PCR and immunohistochemical analysis of a tissue microarray. Regulation of DR4 expression by demethylation or transient transfection is of functional relevance for TRAIL resistance in an ovarian cancer cell line. Hypermethylation of the DR4 promoter could be found in 10 of 36 (27.7%) DNAs isolated from ovarian cancer tissue. In an independent set of 68 ovarian cancer cases, a complete loss or down-regulation of DR4 protein expression was observed 10.3% and 8.8% patients, respectively. A significant (P = 0.019) majority of these patients was below 50 years of age. Our findings show a functional relevance of the level of DR4 expression in ovarian cancer and suggest a substantial contribution of DR4 hypermethylation and consequent loss of DR4 expression to ovarian cancer pathogenesis, particularly in premenopausal patients.

This article has been cited by other articles:

				J. Zhou, G.-D. Lu, C.-S. Ong, C.-N. Ong, and H.-M. Shen Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation Mol. Cancer Ther., July 1, 2008; 7(7): 2170 - 2180. [Abstract] [Full Text] [PDF]

				M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells Cancer Res., May 1, 2008; 68(9): 3440 - 3449. [Abstract] [Full Text] [PDF]

				E. H. Jensen, J. M. Lewis, J. M. McLoughlin, M. D. Alvarado, A. Daud, J. Messina, S. Enkemann, T. J. Yeatman, V. K. Sondak, and A. I. Riker Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma Ann. Surg. Oncol., April 1, 2007; 14(4): 1416 - 1423. [Abstract] [Full Text] [PDF]

				D. Merino, N. Lalaoui, A. Morizot, P. Schneider, E. Solary, and O. Micheau Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. Mol. Cell. Biol., October 1, 2006; 26(19): 7046 - 7055. [Abstract] [Full Text] [PDF]

				P. Horak, D. Pils, A. Kaider, A. Pinter, K. Elandt, C. Sax, C. C. Zielinski, R. Horvat, R. Zeillinger, A. Reinthaller, et al. Perturbation of the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5 Clin. Cancer Res., December 15, 2005; 11(24): 8585 - 8591. [Abstract] [Full Text] [PDF]